Stock chart
Analyses on Imed Infinity (3)
- March 31, 2026March 31, 2026
- Follow-up
Imed Follow-up: How Much of the Portfolio Value Is Actually Accessible to Public Holders
At Imed, gross portfolio value is not the same thing as holder-accessible value. At year-end 2025 there is $2.883 million of cash and $5.149 million of illiquid investments, but there is no distributable surplus, the proposed capital reduction of up to $1 million has been stayed…
- Follow-up
Imed Follow-up: Does Theranica's Valuation Hold Beyond the Series D Round
Theranica's value inside Imed holds up better than a naive ownership-percentage reading, because Imed owns D and C-1 preferred shares that are worth more than common inside the allocation waterfall. It still does not hold up as a fully standalone value, because it explicitly res…
Imed Infinity 2025: GNX Bought Time, but Value Still Depends on Three Private Marks
Imed has moved out of immediate liquidity pressure thanks to the GNX realization and the rights offering, but most of its value still depends on three private holdings and on the ability to convert private marks into accessible value.
